Issue |
J Extra Corpor Technol
Volume 47, Number 4, December 2015
|
|
---|---|---|
Page(s) | 223 - 227 | |
DOI | https://doi.org/10.1051/ject/201547223 | |
Published online | 15 December 2015 |
Case Reports
Factor V Leiden and Cardiopulmonary Bypass
Address correspondence to: Mark W. Rosin, MPS, BSPE, CCP, CPC, Royal University Hospital, 103 Hospital Drive, Saskatoon, SK S7S 1E1, Canada. E-mail: expedition1@sasktel.net
Received:
14
July
2015
Accepted:
13
October
2015
We present a case of a patient with factor V Leiden with an antithrombin III activity of 67% who received a successful aortic valve replacement supported by cardiopulmonary bypass (CPB). A safe level of anticoagulation was achieved by monitoring activated clotting time (ACT) and heparin concentration ensuring adequate anticoagulation throughout the procedure. Results from ACT, heparin dose response, heparin protamine titration, and thrombelastography are given. Factor V Leiden patients can be safely anti-coagulated using heparin for CPB procedures when monitored with ACT, heparin protamine titration, and thrombelastography. Postoperative chest tube losses were 360 mL, less than half our institutional average. Anticoagulation for the pre-and post-operative phase is also discussed.
Key words: cardiopulmonary bypass / anticoagulation / factor V Leiden
© 2015 AMSECT
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.